Samsung unveiled the Watch Active 2 last month and sales are expected to start on September 23rd in the United States, but the ECG and Fall Detection will not available at launch because the company had not yet received approval from the FDA.
Sources speaking for SamMobile now say that Samsung has gotten a timetable for the FDA certification and it will deliver the features in February next year for customers in the United States.
Electrocardiograms will allow the Galaxy Watch Active 2 to provide a much more detailed view onto the workings of your heart and detect possible Atrial Fibrillation (AFib). It's not clear, however, whether this particular feature will make it to users outside the United States, as that would be dependent on country-specific regulations.
The other new feature, Fall Detection, is expected to get a much wider roll-out and it will hit watches for customers in multiple countries outside the US. It's not yet clear whether all countries will get that feature, but it would be much easier for Samsung to get approval from regulators for this feature in comparison to the ECG.
It's also possible that Samsung gives its One UI a visual refresh when it pushes those two new features in Q1 2020.
The Watch Active 2 is the company's first one to use a digital alternative to the rotating bezel where you swipe on the side of the watch to navigate the interface. Customers in Samsung's home market Korea will be the first to get access to the watch, with sales there starting on September 6th.